Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Lancet Haematol. 2017 Jan 12;4(2):e67–e74. doi: 10.1016/S2352-3026(16)30194-6

Figure 1. (A-B). Ruxolitinib treatment reduces symptom scores of patients with CLL.

Figure 1

Waterfall plot showing the mean percentage change from baseline to 3-month scores on BFI (brief fatigue inventory), MDASI (CLL module of the MD Anderson symptom inventory), IS (symptom-associated interference in daily activities) and worst fatigue in 24 hours on BFI scale. Each vertical line represents an individual participant. Significant reductions in symptom scores were observed after ruxolitinib treatment (P<0.0001 in all three scoring systems). The proportion of participants with ≥20% reduction in BFI and/or MDASI score was 78% (32 of 41).